Stocks and Investing
Stocks and Investing
Thu, May 9, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Michael Petusky Maintained (ANIK) at Buy and Held Target at $37 on, May 9th, 2024
Michael Petusky of Barrington Research, Maintained "Anika Therapeutics, Inc." (ANIK) at Buy and Held Target at $37 on, May 9th, 2024.
Michael has made no other calls on ANIK in the last 4 months.
There is 1 other peer that has a rating on ANIK. Out of the 1 peers that are also analyzing ANIK, all agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- George Sellers of "Stephens & Co." Reiterated at Hold and Held Target at $22 on, Thursday, March 14th, 2024
Contributing Sources